ACT

JULY 11/2017


news roundup

CTTI Offers Case Studies in Mobile Tech

The Clinical Trials Transformation Initiative (CTTI) released a set of recommendations and tools that aim to change the use of mobile technology in clinical research.


advertisment

Oracle Health Sciences Webcast: Reimagining Clinical Trials and Unifying Your Clinical Development World
Tuesday, July 25, 2017 at 10:00 AM EDT | 03:00 PM BST | 04:00 PM CEST
Learn about challenges facing the clinical development industry, how to address the challenges with the new Oracle Health Sciences Clinical One™ platform, current capabilities of Clinical One™, what the future holds, and more. Register Now


INC Research Launches Psychiatry Site Network

INC Research has launched its Psychiatry Catalyst Site Network as part of its Catalyst program, to respond to the growth and pipeline of psychiatric studies.


advertisment

Clinical Trial Simulation: An Efficient Tool for Improved Study Designs, Dose Selection and Go/No-go Investment Decisions
Live Webcast: Tuesday, September 19 at 2:00pm BST and Thursday, September 28 at 10am EDT Register now


Accenture Analytics Platform Uses MCC Metrics

Accenture's new analytics Clinical Operations Insights Platform (COIP), is a module of its Life Sciences Cloud for R&D. Accenture joined with the Metrics Champion Consortium (MCC) in the development of COIP, using MCC's industry clinical trial metrics to measure a company's clinical trial performance.


advertisment

A New Paradigm: Cutting-edge Processes and Analytics in Site and Patient Selection
Live Webinar: Thursday, July 20 at 11:00am EDT Register now


More Countries Bid for EMA Headquarters

So widespread is the appetite to host the agency that it was news when Estonia recently stated publicly that it would not put in a bid.


advertisment

Minimal Residual Disease Detection: Key Considerations for Clinical Development in Oncology
On Demand
Learn more

advertisment
Advertisement

In this edition

Supreme Court and FDA Weigh in on Biosimilars
Lessons from DCRI's PALM Registry
Is Pharma Using Patient Endpoints in Study Design?
INC Research Launches Psychiatry Site Network

advertisment

Subscribe

Subscribe

Stay connected with Applied Clinical Trials and sign up for your print or digital issues, as well as our enewsletters.
Subscription offers »


Events

Transformative Trial Models and Engagement
IRT 2017
Global Risk-Based Monitoring, Barcelona
Search Upcoming Events

Blog Posts

Is Pharma Using Patient Endpoints in Study Design?

There is potential to listen to patients in aggregate through the use of big data research. In this article, we will analyze themes from asthma patient conversations via HealthUnlocked, an online healthcare social network, and compare these themes to asthma clinical trial endpoints from large pharma studies.


advertisment

Capturing Continuous Glucose Monitoring Advantages
On Demand
Learn more


Supreme Court and FDA Weigh in on Biosimilars

An important Supreme Court decision in June promises to reduce patent disputes that have threatened to delay when new biosimilars come to market. In clarifying that the “patent dance” does not require biosimilar makers to wait an extra six months after FDA approval to distribute a new product, the unanimous ruling should help overcome delays in future biosimilar sales.


advertisment

Coming to terms with Patient Centricity
On Demand
Learn more

Articles

Lessons from DCRI's PALM Registry

The PALM registry collects data on current practice patterns, patient experiences, and patient and provider knowledge and attitudes to lipid management and the reduction of cardiovascular disease risk. This article discusses the implementation of a tablet-based app for the patients.


advertisment

Shortening Biosimilar Development: A Case Study Integrating Early Clinical (Phase I) with late phase (Phase III) Biosimilars Development
On Demand
Learn more


Six Steps to Ensure Successful Clinical Trial Imaging

A trial can have any number of images from a variety of modalities that require review by clinical expert readers (e.g., radiologists, pathologists, dermatologists, cardiologists), typically at multiple sites. The more variables present, the more opportunities exist for error(s), compliance missteps and subjective, often biased, data.


Read the digital edition of Applied Clinical Trials
Click here to sign up or renew your subscription

Get the full picture


Ask the editor

Lisa Henderson
Editor in Chief
[email protected]

Advertise

Mike Tessalone
Publisher
[email protected]